Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience-Reference-Cited by-同舟云学术

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

Published:2014-10-29 Issue:22 Volume:5 Page:11168-11179
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Hou Ming-Mo¹²,Liu Xiaochun¹,Wheler Jennifer¹,Naing Aung¹,Hong David¹,Coleman Robert L.³,Tsimberidou Apostolia¹,Janku Filip¹,Zinner Ralph¹,Lu Karen³,Kurzrock Razelle⁴,Fu Siqing¹

Affiliation:

1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas

2. Division of Hematology-Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan

3. Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

4. UC San Diego Moores Cancer Center, La Jolla, California

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the Research Progress of Traditional Chinese Medicine in the Intervention of Kidney Deficiency and Blood Stasis Type Osteoporosis by Regulating the PI3K/Akt Signalling Pathway;Journal of Contemporary Medical Practice;2024-08-21

2. Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy;Cancers;2024-05-09

3. Landscape of somatic mutated genes and inherited susceptibility genes in gynecological cancer;Journal of Obstetrics and Gynaecology Research;2023-08-26

4. LKB1/STK11 Tumor Suppressor Reduces Angiogenesis by Directly Interacting with VEGFR2 in Tumorigenesis;Biomolecules & Therapeutics;2023-06-26

5. Targeting Ras signaling excitability in cancer cells through combined inhibition of FAK and PI3K;2023-06-13